Omrix Biopharmaceuticals, Inc. · New York, NY United States
Company Description
View Omrix Biopharmaceuticals, Inc. Locations On A US Map
This link will open in a new window
This link will open in a new window Omrix Biopharmaceuticals helps keep blood in its place in the operating room. The company develops biosealants derived from human plasma to control bleeding during surgical procedures. The biosealants contain naturally occurring proteins that clot and adhere to tissue. Johnson & Johnson 's Ethicon subsidiary markets and distributes these products under the names Evicel in the US and Quixil in Europe. Omrix's Evithrom thrombin product was developed with Ethicon primarily for neurosurgery. The FDA has approved both for hemostasis (minimizing blood loss) during surgery. Omrix was acquired by Johnson & Johnson in 2008 and became part of the Ethicon division. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Key Omrix Biopharmaceuticals, Inc. Financials
| Company Type | Subsidiary Single Location |
| Fiscal Year-End | December |
| Employees | 212 |
Omrix Biopharmaceuticals, Inc. Executives
15 executives listed for Omrix Biopharmaceuticals, Inc.'s New York, NY location.
| Title | Name & Bio | Contact |
| Chairman | Larry Ellberger | Network |
| CEO and Director | Robert Taub | Network |
| President and COO | Nissim Mashiach | Network |
Competition
Competitive Landscape for Omrix Biopharmaceuticals, Inc.
Demand is driven by population demographics and advances in medical knowledge and technology. The profitability of individual companies depends on the ability to develop superior products. Large companies have economies of scale in manufacturing and R&D. Small companies can compete successfully by specializing in a particular market segment, or through technical innovation. To read the full description, subscribe now.Top Omrix Biopharmaceuticals, Inc. Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!